Aratana Therapeutics, Inc. (NASDAQ:PETX) major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $5.70, for a total value of $5,075,941.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, November 29th, Healthcare Master Fun Broadfin sold 116,516 shares of Aratana Therapeutics stock. The stock was sold at an average price of $6.53, for a total value of $760,849.48.

Aratana Therapeutics, Inc. (NASDAQ:PETX) traded down $0.40 on Friday, reaching $5.45. The company had a trading volume of 1,693,865 shares, compared to its average volume of 414,827. Aratana Therapeutics, Inc. has a 52-week low of $4.97 and a 52-week high of $8.63. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The firm had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s revenue for the quarter was up 1440.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.38) earnings per share. analysts predict that Aratana Therapeutics, Inc. will post -1.03 earnings per share for the current year.

Several brokerages have recently commented on PETX. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 18th. HC Wainwright began coverage on Aratana Therapeutics in a research report on Friday, November 17th. They issued a “buy” rating and a $10.00 target price for the company. Jefferies Group set a $9.00 target price on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 16th. BidaskClub cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Aratana Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.75.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PETX. American International Group Inc. boosted its position in Aratana Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,354 shares during the last quarter. Vanguard Group Inc. boosted its position in Aratana Therapeutics by 13.9% during the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after purchasing an additional 235,208 shares during the last quarter. Geode Capital Management LLC boosted its position in Aratana Therapeutics by 4.5% during the first quarter. Geode Capital Management LLC now owns 243,352 shares of the biopharmaceutical company’s stock valued at $1,289,000 after purchasing an additional 10,465 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Aratana Therapeutics by 85.7% during the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 59,181 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Aratana Therapeutics by 17.9% during the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,883 shares during the last quarter. 73.95% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 890,516 Shares” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/aratana-therapeutics-inc-petx-major-shareholder-healthcare-master-fun-broadfin-sells-890516-shares.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.